[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100104627":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":33,"centralContacts":37,"locations":38,"responsibleParty":57,"collaborators":59,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":37,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":92,"whyStopped":37,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Public Health England","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"1","EXPERIMENTAL","Pediacel - 2,3,4 months Prevenar - 2,4 months Menjugate - 3 months Hib\u002F pneumo conjugate\u002F Men C conjugate - 12 months\n\nBlood collected - 4,5,12,13 months",[13],"Biological: Menjugate (Meningococcal C conjugate vaccine)",{"label":15,"type":10,"description":16,"interventionNames":17},"2","Pediacel - 2,3,4 months Prevenar - 2,4 months Neis-vacC - 3 months Hib\u002F pneumo conjugate\u002F Men C conjugate - 12 months\n\nBlood collected - 4,5,12,13 months",[18],"Biological: NeisVacC (Meningococcal C conjugate vaccine)",[20,28],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"BIOLOGICAL","NeisVacC (Meningococcal C conjugate vaccine)","Dosage",[15],[26,27],"Meningococcal C conjugate vaccine","Neis-vacC",{"type":21,"name":29,"description":23,"armGroupLabels":30,"otherNames":31},"Menjugate (Meningococcal C conjugate vaccine)",[9],[26,32],"Menjugate",[34],{"name":35,"affiliation":5,"role":36},"Elizabeth Miller, BSc MBBS FFPHM FRCPath","PRINCIPAL_INVESTIGATOR",null,[39,50],{"facility":40,"status":37,"city":41,"state":37,"zip":37,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":37},"Health Protection Agency","Gloucester","United Kingdom","UK",{"type":45,"coordinates":46},"Point",[47,48],-2.2431,51.86568,{"lat":48,"lon":47},{"facility":40,"status":37,"city":51,"state":37,"zip":37,"country":42,"countryCode":43,"cosmosGeoPoint":52,"geoPoint":56,"contacts":37},"London",{"type":45,"coordinates":53},[54,55],-0.12574,51.50853,{"lat":55,"lon":54},{"type":37,"investigatorFullName":37,"investigatorTitle":37,"investigatorAffiliation":37,"oldNameTitle":58,"oldOrganization":40},"Prof Elizabeth Miller",[60,63],{"name":61,"class":62},"Institute of Child Health","OTHER",{"name":64,"class":6},"National Institute of Biological Standards and Control","100104627","phase-4-study-to-evaluate-the-immune-response-of-united-kingdom-uk-infants-receiving-dtaphibipv-meningococcal-c-conjugate-and-pneumococcal-conjugate-vaccines-antibody-persistence-and-responses-to-booster-doses-in-the-second-year-of-life-100104627",false,"NCT00625677","Study to Evaluate the Immune Response of United Kingdom (UK) Infants Receiving DTaP\u002FHib\u002FIPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life","A Phase IV, Randomized Study to Evaluate the Immune Response of UK Infants Receiving DTaP\u002FHib\u002FIPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life","Sched2","Inclusion Criteria:\n\n* No contraindications to vaccination as specified in the \"Green Book\" - Immunisation Against Infectious Disease, HMSO.\n* Written informed consent obtained from the parent or legal guardian of the infant\n* Infant aged no less than 7 weeks exactly, and no more than 11 weeks 6 days\n\nExclusion Criteria:\n\n* None",true,"ALL","7 Weeks","12 Weeks",{"count":78,"type":79},130,"ESTIMATED","INTERVENTIONAL",[82],"PHASE4","The purpose of this study is:\n\nTo assess whether there are differences in antibody persistence eight months post primary (pre-booster) or in responses to the booster with regard to the Meningococcal C Conjugate (MCC) vaccine given in infancy.\n\nTo examine levels of diphtheria and tetanus antibody pre- and post-booster, with regard to the carrier proteins contained in the conjugate vaccines.",[85,86],"Meningococcal Infections","Pneumococcal Infections",[88,89,90,91],"meningococcal serogroup C vaccine","reduced dose","meningococcal serogroup C conjugate vaccine","pneumococcal conjugate vaccine","COMPLETED","2019-03-20",{"date":95,"type":96},"2019-03-22","ACTUAL",{"date":98,"type":37},"2008-02",{"date":100,"type":96},"2010-03",{"name":5,"class":6},2]